Episode
Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.
- Podcast
- Business Of Biotech
- Published
- May 11, 2026
- Duration seconds
- 3252
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/building-a-new-antibody-discovery-platform-with-infinimmune-s-wyatt-mcdonnell-ph-d/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/building-a-new-antibody-discovery-platform-with-infinimmune-s-wyatt-mcdonnell-ph-d.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Wyatt McDonnell, Ph.D., cofounder and CEO at Infinimmune, talks about how single-cell biology and computational rigor led to the formation of Infinimmune, and a new way to discover human-derived antibody drugs. Wyatt explains Infinimmune's 'discovered in humans' antibody discovery platform, how the company was launched and initially funded, and how Infinimmune landed a Merck collaboratio...